EXPLORE G2D2’S COLLABORATIVE APPROACH
Click on any discipline to see what goes into it and how it all comes together.
A novel, genetically validated target modulating immune mechanisms to treat dementia.
CHOOSE THE RIGHT TARGET
Finding a disease risk-associated gene is just the first step in the drug development journey. We begin by understanding the connection between a risk or a protection-associated genetic variant and the underlying biology of disease.
The Immunodementia Biology group works closely with colleagues in Data Sciences to dissect risk variant effects on protein and cell functions, and to establish disease-relevant assays that reflect target activity. Working internally and with collaborators, we’re always trying to expand the biology around our targets.
ADVANCE FROM MECHANISM TO THERAPY
We apply an array of technologies to find and optimize molecules that will turn disease processes towards a more-healthy function. Following through, we analyze the effects of our candidate drugs in relevant in-vitro, in-vivo and ex-vivo systems, and explore molecular markers that will help us choose appropriate patient populations and assess drug effects in clinic. Unbiased ’omics’ approaches give us a comprehensive view of disease mechanisms and compound effects, while cutting-edge optical imaging provides critical mechanistic insights.
UNPRECEDENTED TECHNOLOGY ADVANCEMENTS IN GENETICS, CELL BIOLOGY, IMAGING AND SINGLE-CELL OR SYSTEM-LEVEL ’OMICS’ APPROACHES RESULTED IN THE DISCOVERY OF NOVEL TARGETS AND PATHWAY BIOLOGIES. AT G2D2, WE HARNESS THESE TECHNOLOGIES TO UNDERSTAND MICROGLIA FUNCTION WITHIN THE DISEASE STATE AND USE DIFFERENT MODALITIES TO MODULATE MICROGLIA FUNCTION/PHENOTYPE AS A POTENTIAL THERAPEUTIC APPROACH FOR TREATING ALZHEIMER’S DISEASE.
Head, Immunodementia Biology, G2D2